Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIRFLO: Ziresovir in Hospitalized Infants with RSV
NCT04231968Phase 3Completed
- Sponsor
- Ark Biosciences
- Start
- Sep 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ziresovir in respiratory syncytial virus infection (RSV), sponsored by Ark Biosciences. Started Sep 2020; status: completed.
02
Drugs
ziresovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04231968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04231968.